CMRA Pengajuan SEC - Comera Life Sciences Holdings, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1907685

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Comera Life Sciences Holdings, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 26, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	POS AM	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	POS AM	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	POS AM	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	POS AM	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Nos.
February 26, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
January 30, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
January 30, 2024	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 13 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A C
January 30, 2024	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 13 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no.13 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which f
January 30, 2024	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 13 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 13 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which
January 8, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm242192d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
January 8, 2024	SC 13D	CMRA / Comera Life Sciences Holdings, Inc. / Cherington Charles - SC 13D Activist Investment SC 13D 1 tm242192d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) Charles Cherington c/o Ara Partners 200 Berkeley Street, 26th Floor Boston, MA 02116 (
January 4, 2024	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 12 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which
January 4, 2024	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 12 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A C
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Comera Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
January 4, 2024	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 12 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no.12 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which f
January 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Comera Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
December 29, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 11 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A C
December 29, 2023	EX-4.1	FORM OF SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.1 FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOL
December 29, 2023	EX-4.1	FORM OF SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.1 FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOL
December 29, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t
December 29, 2023	EX-4.2	COMMON STOCK PURCHASE WARRANT COMERA LIFE SCIENCES HOLDINGS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 29, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 11 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no.11 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which f
December 29, 2023	EX-4.2	COMMON STOCK PURCHASE WARRANT COMERA LIFE SCIENCES HOLDINGS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 29, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 11 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which
December 29, 2023	EX-4.1	FORM OF SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.1 FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOL
December 29, 2023	EX-4.2	COMMON STOCK PURCHASE WARRANT COMERA LIFE SCIENCES HOLDINGS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 29, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
December 29, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t
December 29, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t
December 29, 2023	EX-4.1	FORM OF SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.1 FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOL
December 29, 2023	EX-4.2	COMMON STOCK PURCHASE WARRANT COMERA LIFE SCIENCES HOLDINGS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 29, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t
December 6, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 10 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no.10 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which f
December 6, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
December 6, 2023	EX-99.1	Comera Life Sciences Announces Process Exploring Strategic Alternatives Exhibit 99.1 Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass. December 6, 2023 — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternat
December 6, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 10 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which
December 6, 2023	EX-99.1	Comera Life Sciences Announces Process Exploring Strategic Alternatives Exhibit 99.1 Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass. December 6, 2023 — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternat
December 6, 2023	EX-99.1	Comera Life Sciences Announces Process Exploring Strategic Alternatives Exhibit 99.1 Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass. December 6, 2023 — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternat
December 6, 2023	EX-99.1	Comera Life Sciences Announces Process Exploring Strategic Alternatives Exhibit 99.1 Comera Life Sciences Announces Process Exploring Strategic Alternatives WOBURN, Mass. December 6, 2023 — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternat
December 6, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 10 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A C
November 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Comera Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
November 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 9 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
November 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 9 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 9 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 9, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 8 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-41403 Comera Life Sciences Holdings, Inc.
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
November 9, 2023	EX-99.1	Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights – Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Exp Exhibit 99.1 Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights – Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technolo
November 9, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 8 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 9, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 8 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 3, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 7 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
November 3, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 7 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 3, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 7 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
November 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Comera Life Scie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
October 11, 2023	EX-10.1	12 Gill Street Suite 4650 ∙ Woburn MA 01801 12 Gill Street Suite 4650 ∙ Woburn MA 01801 October 6, 2023 PERSONAL AND CONFIDENTIAL Dr.
October 11, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 6 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
October 11, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 6 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
October 11, 2023	EX-10.1	12 Gill Street Suite 4650 ∙ Woburn MA 01801 12 Gill Street Suite 4650 ∙ Woburn MA 01801 October 6, 2023 PERSONAL AND CONFIDENTIAL Dr.
October 11, 2023	EX-10.1	12 Gill Street Suite 4650 ∙ Woburn MA 01801 12 Gill Street Suite 4650 ∙ Woburn MA 01801 October 6, 2023 PERSONAL AND CONFIDENTIAL Dr.
October 11, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 6 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
October 6, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
October 6, 2023	EX-10.1	12 Gill Street Suite 4650 ∙ Woburn MA 01801 12 Gill Street Suite 4650 ∙ Woburn MA 01801 Exhibit 10.1 October 6, 2023 Dr. Neal Muni Re: Separation Agreement Dear Neal: As we discussed, your employment with Comera Life Sciences, Inc. (the “Company”), a wholly owned subsidiary of Comera Life Sciences Holdings, Inc. (“Parent”), will end effective October 6, 2023 (hereinafter, the “Separation Date”). On the Separation Date, you will receive a pa
October 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 Comera Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
September 13, 2023	424B3	27,863,058 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(3) Registration No. 333-274253 PROSPECTUS 27,863,058 SHARES OF COMMON STOCK This prospectus relates to the offer and resale from time to time by the Selling Stockholders named in this prospectus (the “Selling Stockholders”) or their permitted transferees of up to 27,863,058 shares of common stock, $0.0001 par value per share (the “Common Stock”) of Comera Life Science
September 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Comera Life Sc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation
September 12, 2023	S-8	As filed with the Securities and Exchange Commission on September 12, 2023 As filed with the Securities and Exchange Commission on September 12, 2023 Registration No.
September 12, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Comera Life Sciences Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Comera Life Sciences Holdings, Inc.
September 11, 2023	CORRESP	Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 September 11, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-3 File No. 333-274253 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under th
September 8, 2023	SC 13D/A	CMRA / Comera Life Sciences Holdings Inc / Cherington Charles - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) Charles Cherington c/o Ara Partners 5300 Memorial Drive, Suite 500 Houston, Texas 77007 (713) 817-5702 (
September 6, 2023	SC 13G/A	CMRA / Comera Life Sciences Holdings Inc / IAF, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) IAF, LLC c/o 115 Church Street Charleston, SC 29401 (843) 577-2300 (Name, Address and Telephone Number
September 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Comera Life Scien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
September 1, 2023	EX-10.1	COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the “Compa
September 1, 2023	EX-10.1	COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the “Compa
September 1, 2023	EX-10.1	COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the “Compa
September 1, 2023	EX-10.1	COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the “Compa
September 1, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 5 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
September 1, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 5 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
September 1, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 5 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
August 29, 2023	S-3	As filed with the Securities and Exchange Commission on August 29, 2023 As filed with the Securities and Exchange Commission on August 29, 2023 Registration Statement No.
August 29, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) COMERA LIFE SCIENCES HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) COMERA LIFE SCIENCES HOLDINGS, INC.
August 28, 2023	SC 13D/A	CMRA / Comera Life Sciences Holdings Inc / Cherington Charles - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) Charles Cherington c/o Ara Partners 5300 Memorial Drive, Suite 500 Houston, Texas 77007 (713) 817-5702 (
August 24, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ea183895ex99-1comera.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing
August 24, 2023	SC 13G	CMRA / Comera Life Sciences Holdings Inc / Singer Nicholas Jason - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 20037C108 (CUSIP Number) May 19, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
August 16, 2023	SC 13G	CMRA / Comera Life Sciences Holdings Inc / OTR Acquisition Sponsor LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 20037C108 (CUSIP Number) May 19, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
August 11, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid
August 10, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 4 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
August 10, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
August 10, 2023	EX-99.1	Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights – Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – –Receive Exhibit 99.1 Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights – Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – –Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain
August 10, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 4 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
August 10, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 4 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-41403 Comera Life Sciences Holdings, Inc.
August 10, 2023	SC 13G	CMRA / Comera Life Sciences Holdings Inc / IAF, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) IAF, LLC c/o 115 Church Street Charleston, SC 29401 (843) 577-2300 (Name, Address and Telephone Number o
August 4, 2023	SC 13D/A	CMRA / Comera Life Sciences Holdings Inc / Soane David - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) David Soane c/o Soane Labs, LLC 380 NE 72nd Terrace Miami, FL 33138 510-376-1425 (Name, Address
August 1, 2023	EX-99.1	Comera Life Sciences Announces $4.1 Million Private Placement Exhibit 99.1 Comera Life Sciences Announces $4.1 Million Private Placement WOBURN, Mass. August 1, 2023 — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares o
August 1, 2023	EX-4.1	Form of Common Stock Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
August 1, 2023	EX-10.1	Securities Purchase Agreement, dated July 31, 2023, by and among the Company and the Purchasers defined therein Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 31, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to th
August 1, 2023	EX-10.2	Registration Rights Agreement dated July 31, 2023, by and among the Company and the Purchasers defined therein EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 31, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the “Company”), and each of the purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securit
August 1, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Co
August 1, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid
May 19, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 3 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 19, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 3 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
May 19, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 3 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 19, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Com
May 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
May 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 16, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 12, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 12, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Co
May 12, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Com
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-41403 Comera Life Sciences Holdings, Inc.
May 12, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 2 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) which fo
May 12, 2023	EX-99.1	Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights – Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Com Exhibit 99.1 Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights – Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera’s patent portf
May 5, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Comm
May 5, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve 424B3 1 d417483d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 1 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable up
May 5, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock 424B3 1 d417483d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 1 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to
May 5, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 1 (To Prospectus dated March 30, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated March 30, 2023 (as amended or supplemented from time to time, the “Prospectus”) wh
March 31, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 PROSPECTUS Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus relates to the offer and resale of up to 5,000,000 shares of common stock, $0.0001 par value per share (the “Holdco Common Stock”) of Comera Life Sciences Holdings, Inc. (“Holdco,” “we,” “us,” “our” or the “Company”), by Arena Business Solutio
March 31, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 PROSPECTUS Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Convertible Perpetual Preferred Stock offered by Selling
March 31, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 PROSPECTUS Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the Selling Stockholders named in this prospectus (the “Selling Stockholders”) or their permitted transferees of up to 7,218,726 shares of common stock, $0.0001 par value per share (the “Hol
March 27, 2023	POS AM	As filed with the U.S. Securities and Exchange Commission on March 27, 2023 As filed with the U.S. Securities and Exchange Commission on March 27, 2023 Registration No. 333-264686 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or
March 27, 2023	POS AM	As filed with the U.S. Securities and Exchange Commission on March 27, 2023 As filed with the U.S. Securities and Exchange Commission on March 27, 2023 Registration No. 333-267283 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or
March 27, 2023	POS AM	As filed with the U.S. Securities and Exchange Commission on March 27, 2023 As filed with the U.S. Securities and Exchange Commission on March 27, 2023 Registration No. 333-269564 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or
March 24, 2023	EX-99.1	This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as “may,” “might,” “could,” “will,” “would,” “should,” “ EX-99.1 Corporate Presentation March 2023 Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as “may,” “might,” “could,” “will,” “would,” “should,” “expect,” “possible,” “potential,” “anticipate,” “contemplate,” “believe,” “estimate,” “plan,” “
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Comera Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (C
March 17, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Comera Life Sciences Holdings, Inc.
March 17, 2023	EX-4	Description of Securities. Exhibit 4.6 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the securities of Comera Life Sciences Holdings, Inc. (the “Company”) as of March 17, 2023, and is subject in all respects to the applicable provisions of the Delaware General Corporation Law (the “DGCL”), to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”), Certific
March 17, 2023	EX-10	Form of Nonstatutory Stock Option Agreement (Inducement Award) (incorporated by reference to Exhibit 10.7 to the Annual Report on Form 10-K filed by the Registrant with the SEC on March 17, 2023). Exhibit 10.7 COMERA LIFE SCIENCES HOLDINGS, INC. NONSTATUTORY STOCK OPTION AWARD AGREEMENT Comera Life Sciences Holdings, Inc. (the “Company”), hereby grants to [] (the “Holder”) an option (the “Option”) to purchase a total of [] shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at the price and on the terms set forth in this Comera Life Sciences Holdings, Inc
March 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-41403 COMERA LIFE SCIEN
March 17, 2023	S-8	As filed with the Securities and Exchange Commission on March 17, 2023 S-8 As filed with the Securities and Exchange Commission on March 17, 2023 Registration No.
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Comera Life Scienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (C
March 16, 2023	EX-99.1	Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights – Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 EX-99.1 Exhibit 99.1 Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights – Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel dis
February 21, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 4 (To Prospectus dated September 15, 2022) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated September 15, 2022 (as amended or supplemented from time to time, the “Prospec
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Comera Life Sci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
February 21, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock 424B3 1 d427260d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Supplement No. 1 (To Prospectus dated February 10, 2023) Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated February 10, 2023 (as amended or supplemented from ti
February 21, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 7 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series
February 10, 2023	424B3	Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock 424B3 1 d424453d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269564 Prospectus Comera Life Sciences Holdings, Inc. 7,218,726 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the Selling Stockholders named in this prospectus (the “Selling Stockholders”) or their permitted transferees of up to 7,218,726 shares of c
February 8, 2023	S-1/A	As filed with the U.S. Securities and Exchange Commission on February 8, 2023 S-1/A As filed with the U.S. Securities and Exchange Commission on February 8, 2023 Registration No. 333-269564 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or Other
February 8, 2023	CORRESP	Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 CORRESP 1 filename1.htm Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 February 8, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-1 File No. 333-269564 Request for Acceleration Ladies and Gentlemen: Pursuan
February 3, 2023	EX-10.14	Offer Letter Agreement dated October 25, 2022, between Comera Life Sciences Holdings, Inc. and Janice McCourt (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 filed by the Registrant with the SEC on February 3, 2023. EX-10.14 Exhibit 10.14 October 25, 2022 Ms. Janice McCourt [***] Re: Employment Offer Dear Janice: I am pleased to offer you employment with Comera Life Sciences, Inc. (the “Company”). The terms of your employment, should you accept this offer, are as set forth in this letter agreement (the “Agreement”). 1. Position. Your position will be Chief Business Officer (the “CBO”). You will have such duti
February 3, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES 5 d424453dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Comera Life Sciences Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or carry forward rule Rule Amount Registered(1) Proposed Maximum Offe
February 3, 2023	S-1	As filed with the U.S. Securities and Exchange Commission on February 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life S Table of Contents As filed with the U.S. Securities and Exchange Commission on February 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or Other Jurisdiction
January 10, 2023	SC 13G	US20037C1080 / COMERA LIFE SCIENCES HOLDINGS INC / Freebird Partners LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common stock, par value $0.0001 per share Warrants (Title of Class of Securities) 20037C108 (CUSIP Number) January 4, 2023 (Date of Event which Requires Filing of this Statement) Check the approp
January 10, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d387306dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, $0.0001 par value per share, of Comera Life Sciences Holdings, Inc., a Delaware corporation, dated as of January 10, 2023, is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the under
January 9, 2023	SC 13D/A	US20037C1080 / COMERA LIFE SCIENCES HOLDINGS INC / Soane David - SC 13D/A Activist Investment SC 13D/A 1 d447880dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) David Soane c/o Soane Labs, LLC 380 NE 72nd Terrace Miami, FL 331
January 6, 2023	EX-99.1	This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as “may,” “might,” “could,” “will,” “would,” “should,” “ Corporate Presentation January 2023 Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as ?may,? ?might,? ?could,? ?will,? ?would,? ?should,? ?expect,? ?possible,? ?potential,? ?anticipate,? ?contemplate,? ?believe,? ?estimate,? ?plan,? ?predic
January 6, 2023	SC 13D/A	US20037C1080 / COMERA LIFE SCIENCES HOLDINGS INC / Cherington Charles - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) Charles Cherington c/o Ara Partners 5300 Memorial Drive, Suite 500 Houston, Texas 77007 (713) 817-5702 (
January 6, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
January 5, 2023	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock 424B3 1 d441188d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 3 (To Prospectus dated September 15, 2022) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) updates, amends and supplements the prospectus dated September 15, 2022 (as amended or supplemented from
January 5, 2023	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 6 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
January 4, 2023	EX-4.1	Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on January 4, 2023). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
January 4, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2023 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
January 4, 2023	EX-10.1	Securities Purchase Agreement dated January 2, 2023, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on January 4, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 2, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to
January 4, 2023	EX-10.2	Registration Rights Agreement dated January 4, 2023, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant with the SEC on January 4, 2023). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of January 4, 2023, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the ?Company?), and each of the purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Pu
January 4, 2023	EX-99.1	Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules Exhibit 99.1 Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules WOBURN, Mass.?January 4, 2023? Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private placement to exi
November 23, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
November 23, 2022	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 2 (To Prospectus dated September 15, 2022) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 2 (this ?Prospectus Supplement?) updates, amends and supplements the prospectus dated September 15, 2022 (as amended or supplemented from time to time, the ?Prospectus?)
November 23, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 5 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
November 14, 2022	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 1 (To Prospectus dated September 15, 2022) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 1 (this ?Prospectus Supplement?) updates, amends and supplements the prospectus dated September 15, 2022 (as amended or supplemented from time to time, the ?Prospectus?)
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-41403 Comera Life Sciences Holdings, Inc.
November 14, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 4 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
November 14, 2022	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Prospectus Supplement No. 1 (To Prospectus dated September 15, 2022) Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus supplement no. 1 (this ?Prospectus Supplement?) updates, amends and supplements the prospectus dated September 15, 2022 (as amended or supplemented from time to time, the ?Prospectus?)
November 14, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 4 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
November 10, 2022	EX-99.1	Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights – Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formu Exhibit 99.1 Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights ? Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company ? ? Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) ? WOBURN, Mass.?Nov
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
October 28, 2022	SC 13D	US20037C1080 / COMERA LIFE SCIENCES HOLDINGS INC / Soane David - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) David Soane c/o Soane Labs, LLC 380 NE 72nd Terrace Miami, FL 33138 510-376-1425 (Name, Address an
October 28, 2022	EX-99.1	JOINT FILING AGREEMENT EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each sh
September 15, 2022	424B3	Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267283 Comera Life Sciences Holdings, Inc. 5,000,000 Shares of Common Stock This prospectus relates to the offer and resale of up to 5,000,000 shares of common stock, $0.0001 par value per share (the ?Holdco Common Stock?) of Comera Life Sciences Holdings, Inc. (?Holdco,? ?we,? ?us,? ?our? or the ?Company?), by Arena Business
September 13, 2022	CORRESP	Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 September 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-1 File No. 333-267283 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under th
September 13, 2022	SC 13D	US20037C1080 / COMERA LIFE SCIENCES HOLDINGS INC / Cherington Charles - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) Charles Cherington c/o Ara Partners 5300 Memorial Drive, Suite 500 Houston, Texas 77007 (713) 817-5702 (N
September 6, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Comera Life Sciences Holdings, Inc.
September 6, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation)
September 6, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 3 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
September 6, 2022	S-1	As filed with the U.S. Securities and Exchange Commission on September 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Table of Contents As filed with the U.S. Securities and Exchange Commission on September 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or Other Jurisdiction
September 6, 2022	EX-99.1	INDEX TO FINANCIAL STATEMENTS COMERA LIFE SCIENCES, INC. Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS COMERA LIFE SCIENCES, INC. Index to Financial Statements as of December 31, 2021 and 2020 and for the Years Then Ended Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheets F-3 Statements of Operations and Comprehensive Loss F-4 Statements of Convertible Preferred Stock, Stockholders? Deficit and Members? Equity F-5 Statements of
August 31, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 2 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
August 31, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
August 31, 2022	EX-10.1	Purchase Agreement, dated August 31, 2022, between the Registrant and Arena Business Solutions Global SPC II, Ltd. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on August 31, 2022). Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this ?Agreement?) dated as of August 31, 2022 is made by and between ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD., a Cayman Islands exempt company (the ?Investor?), and COMERA LIFE SCIENCES HOLDINGS, INC., Delaware corporation (the ?Company?). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, th
August 31, 2022	EX-99.1	Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions Exhibit 99.1 Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions WOBURN, Mass. — August 31, 2022 — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced entry into a purchase a
August 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (
August 15, 2022	EX-10.1	Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the ?Plan?) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the ?Compa
August 15, 2022	EX-10.2	Form of Nonstatutory Stock Option Agreement under the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. Exhibit 10.2 NONSTATUTORY STOCK OPTION AGREEMENT UNDER THE COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (as amended through the date hereof, the ?Plan?), Comera Life Sciences Holdings, Inc. (
August 15, 2022	EX-2.1	Business Combination Agreement, dated as of January 31, 2022, among the Registrant, OTR Acquisition Corp., CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp. and Comera Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 2.1 BUSINESS COMBINATION AGREEMENT by and among OTR Acquisition Corp., Comera Life Sciences Holdings, Inc., CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp. and Comera Life Sciences, Inc. Dated as of January 31, 2022 ARTICLE I. DEFINITIONS 3 Section 1.01 Certain Definitions 3 Section 1.02 Further Definitions 14 Section 1.03 Construction 16 ARTICLE II. AGREEMENT AND PLAN OF MERGER 17 Section
August 15, 2022	EX-10.3	Form of Incentive Stock Option Agreement under the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 10.3 INCENTIVE STOCK OPTION AGREEMENT UNDER THE COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (as amended through the date hereof, the ?Plan?), Comera Life Sciences Holdings, Inc. (the
August 15, 2022	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 01:22 PM 05/19/2022 FILED 01:22 PM 05/19/2022 SR 20222140396 - File Number 6554758 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COMERA LIFE SCIENCES HOLDINGS, INC. May 19, 2022 Camera Life Sciences Holdings, Inc. (the ?Corporation?), a corporation existing under the General Corporation Law of the State of D
August 15, 2022	EX-10.12	Stockholder Support Agreement, dated as of January 31, 2022, by and among the Registrant, OTR Acquisition Corp., Comera Life Sciences, Inc. and certain stockholders of Comera Life Sciences, Inc. party thereto (incorporated by reference to Exhibit 10.12 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 10.12 STOCKHOLDER SUPPORT AGREEMENT STOCKHOLDER SUPPORT AGREEMENT, dated as of January 31, 2022 (this ?Agreement?), by and among OTR Acquisition Corp., a Delaware corporation (?SPAC?), Comera Life Sciences Holdings, Inc., a Delaware corporation (?Holdco?) and certain of the stockholders of Comera Life Sciences, Inc., a Delaware corporation (the ?Company?), whose names appear on the signatu
August 15, 2022	EX-4.4	Assignment, Assumption and Amendment to OTR Warrant Agreement among OTR Acquisition Corp., the Registrant and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.4 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). EX-4.4 5 cmra-ex44.htm EX-4.4 Exhibit 4.4 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (this “Agreement”), dated May 19, 2022, is made by and among OTR Acquisition Corp., a Delaware corporation (the “Company”), Comera Life Sciences Holdings, Inc., a Delaware corporation (“Holdco”), and Continental Stock Transfer & Trust Company, a New York corp
August 15, 2022	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant of the Registrant (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 01:22 PM 05/19/2022 FILED 01:22 PM 05/19/2022 SR 20222140396 - File Number 6554758 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COMERA LIFE SCIENCES HOLDINGS, INC. May 19, 2022 Camera Life Sciences Holdings, Inc. (the ?Corporation?), a corporation existing under the General Corporation Law of the State of D
August 15, 2022	EX-2.1	Business Combination Agreement, dated as of January 31, 2022, among the Registrant, OTR Acquisition Corp., CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp. and Comera Life Sciences, Inc. Exhibit 2.1 BUSINESS COMBINATION AGREEMENT by and among OTR Acquisition Corp., Comera Life Sciences Holdings, Inc., CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp. and Comera Life Sciences, Inc. Dated as of January 31, 2022 ARTICLE I. DEFINITIONS 3 Section 1.01 Certain Definitions 3 Section 1.02 Further Definitions 14 Section 1.03 Construction 16 ARTICLE II. AGREEMENT AND PLAN OF MERGER 17 Section
August 15, 2022	EX-10.14	Letter Agreement dated May 19, 2022, by and between the Registrant and OTR Acquisition Sponsor LLC (incorporated by reference to Exhibit 10.14 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 10.14 May 19, 2022 OTR Acquisition Sponsor LLC 1395 Brickell Avenue, Suite 800 Miami, FL 33131 Attention: Nicholas Singer Email: [email protected] Re: Board Observer Right Ladies and Gentlemen: This letter agreement (this ?Letter Agreement?) will confirm our agreement that OTR Acquisition Sponsor LLC, a Delaware limited liability company (?Sponsor?), shall be entitled to the following con
August 15, 2022	EX-10.2	Form of Nonstatutory Stock Option Agreement under the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 10.2 NONSTATUTORY STOCK OPTION AGREEMENT UNDER THE COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (as amended through the date hereof, the ?Plan?), Comera Life Sciences Holdings, Inc. (
August 15, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Prospectus Supplement No. 1 (To Prospectus dated June 24, 2022) Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Con
August 15, 2022	EX-10.1	Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 10.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the ?Plan?) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the ?Compa
August 15, 2022	EX-10.14	Letter Agreement, dated May 19, 2022, by and between the Registrant and OTR Acquisition Sponsor LLC. Exhibit 10.14 May 19, 2022 OTR Acquisition Sponsor LLC 1395 Brickell Avenue, Suite 800 Miami, FL 33131 Attention: Nicholas Singer Email: [email protected] Re: Board Observer Right Ladies and Gentlemen: This letter agreement (this ?Letter Agreement?) will confirm our agreement that OTR Acquisition Sponsor LLC, a Delaware limited liability company (?Sponsor?), shall be entitled to the following con
August 15, 2022	EX-3.3	Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 15, 2022). Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF COMERA LIFE SCIENCES HOLDINGS, INC. (THE ?CORPORATION?) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporati
August 15, 2022	EX-4.4	Assignment, Assumption and Amendment to OTR Warrant Agreement among OTR Acquisition Corp., the Registrant and Continental Stock Transfer & Trust Company. Exhibit 4.4 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (this ?Agreement?), dated May 19, 2022, is made by and among OTR Acquisition Corp., a Delaware corporation (the ?Company?), Comera Life Sciences Holdings, Inc., a Delaware corporation (?Holdco?), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in
August 15, 2022	EX-10.3	Form of Incentive Stock Option Agreement under the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. Exhibit 10.3 INCENTIVE STOCK OPTION AGREEMENT UNDER THE COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (as amended through the date hereof, the ?Plan?), Comera Life Sciences Holdings, Inc. (the
August 15, 2022	EX-99.1	Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022 Exhibit 99.1 Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022 WOBURN, Mass.?August 10, 2022? Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial
August 15, 2022	EX-3.3	Amended and Restated Bylaws of the Registrant. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF COMERA LIFE SCIENCES HOLDINGS, INC. (THE ?CORPORATION?) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporati
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-41403 Comera Life Sciences Holdings, Inc.
August 15, 2022	EX-10.12	Stockholder Support Agreement, dated as of January 31, 2022, by and among the Registrant, OTR Acquisition Corp., Comera Life Sciences, Inc. and certain stockholders of Comera Life Sciences, Inc. party thereto. Exhibit 10.12 STOCKHOLDER SUPPORT AGREEMENT STOCKHOLDER SUPPORT AGREEMENT, dated as of January 31, 2022 (this ?Agreement?), by and among OTR Acquisition Corp., a Delaware corporation (?SPAC?), Comera Life Sciences Holdings, Inc., a Delaware corporation (?Holdco?) and certain of the stockholders of Comera Life Sciences, Inc., a Delaware corporation (the ?Company?), whose names appear on the signatu
August 12, 2022	EX-4.1	Amended and Restated Certificate of Incorporation of the Registrant Exhibit 4.1 State of Delaware Secretary of State Division of Corporations Delivered 01:22 PM 05/19/2022 FILED 01:22 PM 05/19/2022 SR 20222140396 - File Number 6554758 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COMERA LIFE SCIENCES HOLDINGS, INC. May 19, 2022 Camera Life Sciences Holdings, Inc. (the “Corporation”), a corporation existing under the General Corporation Law of the State of D
August 12, 2022	EX-99.1	Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan Exhibit 99.1 COMERA LIFE SCIENCES HOLDINGS, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1 Purposes of the Plan The purposes of the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences Holdings, Inc. (the “Compa
August 12, 2022	EX-4.3	Amended and Restated Bylaws of the Registrant Exhibit 4.3 AMENDED AND RESTATED BYLAWS OF COMERA LIFE SCIENCES HOLDINGS, INC. (THE ?CORPORATION?) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporati
August 12, 2022	S-8	As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.
August 12, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 8 d340015dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Comera Life Sciences Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Pri
July 29, 2022	EX-16.1	Letter from WithumSmith+Brown, PC to the U.S. Securities and Exchange Commission. Exhibit 16.1 July 28, 2022 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Comera Life Sciences Holdings, Inc. (?Comera?) statements included under Item 4.01 (a) of its Form 8-K dated July 28, 2022. We agree with the statements concerning our Firm under Item 4.01 (a), in which we were informed of our dismi
July 29, 2022	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Co
June 28, 2022	424B3	Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conve 424B3 1 d619951d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264686 Comera Life Sciences Holdings, Inc. 1,946,846 Warrants to Purchase Common Stock 15,093,712 Shares of Common Stock Including 1,946,846 Shares of Common Stock issuable upon the exercise of Warrants and 342,755 Shares of Common Stock issuable upon conversion of the Series A Convertible Perpe
June 23, 2022	S-1/A	Form S-1/A Table of Contents As filed with the U.S. Securities and Exchange Commission on June 22, 2022 Registration No. 333-264686 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State
June 22, 2022	CORRESP	Comera Life Sciences Holdings, Inc. 12 Gill Street Suite 4650 Woburn, Massachusetts 01801 Tel: (617) 871-2101 Comera Life Sciences Holdings, Inc. 12 Gill Street Suite 4650 Woburn, Massachusetts 01801 Tel: (617) 871-2101 June 22, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-1 File No. 333-264686 Dear Mr. Campbell: Pursuant to R
June 17, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Co
June 17, 2022	EX-10.1	Offer Letter Agreement dated June 13, 2022, between Comera Life Sciences Holdings, Inc. and Michael Campbell (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 17, 2022). EX-10.1 2 d332106dex101.htm EX-10.1 Exhibit 10.1 June 13, 2022 Mr. Michael Campbell Re: Employment Offer Dear Michael: I am pleased to offer you employment with Comera Life Sciences, Inc. (the “Company”). The terms of your employment, should you accept this offer, are as set forth in this letter agreement (the “Agreement”). 1. Position. Your position will be Executive Vice President and Chief Fina
June 16, 2022	SC 13G/A	CMRA / Comera Life Sciences Holdings Inc / Rabinowitz Michael - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
June 16, 2022	EX-1	Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of Common Stock of Comera Life Sciences Holdings, Inc.
June 3, 2022	SC 13G	CMRA / Comera Life Sciences Holdings Inc / Rabinowitz Michael - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
June 3, 2022	EX-99.1	Exhibit 1 Exhibit 1 SCHEDULE 13G CUSIP NO. 20037C108 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to 967,520 shares of Common Stock of Comera Life Sciences Holdings, Inc. and further agree that this Jo
June 3, 2022	S-1/A	As filed with the U.S. Securities and Exchange Commission on June 2, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 2, 2022 Registration No. 333-264686 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State o
June 3, 2022	EX-21.1	List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 filed by the Registrant with the SEC on May 5, 2022). EXHIBIT 21.1 Comera Life Sciences Holdings, Inc. Delaware Corporation Subsidiaries (100% ownership): Comera Life Sciences, Inc. Delaware Corporation OTR Acquisition Corp. Delaware Corporation
June 2, 2022	CORRESP	June 2, 2022 345 Park Avenue New York, NY 10154-1895 Direct Main Fax 212.407.4000 212.407.4000 212.407.4990 June 2, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell and Celeste Murphy Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-1 Filed May 5, 2022 File No. 333-264686 De
May 31, 2022	SC 13G	CMRA / Comera Life Sciences Holdings Inc / Phoenix Venture Partners LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Comera Life Sciences Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 20037C108 (CUSIP Number) May 19, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
May 31, 2022	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d317846dex991.htm EX-99.1 CUSIP No. 20037C108 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of May 31, 2022, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned o
May 25, 2022	EX-21.1	List of subsidiaries of the Registrant. EX-21.1 9 d360099dex211.htm EX-21.1 Exhibit 21.1 List of Subsidiaries of Comera Life Sciences Holdings, Inc. Subsidiary Name State or other jurisdiction of incorporation or organization Names under which such subsidiaries do business Comera Life Sciences, Inc. Delaware subsidiary name OTR Acquisition Corp. Delaware subsidiary name
May 25, 2022	EX-3.3	Certificate of Designation of the Series A Convertible Perpetual Preferred Stock (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 25, 2022). EX-3.3 3 d360099dex33.htm EX-3.3 Exhibit 3.3 CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PERPETUAL PREFERRED STOCK OF COMERA LIFE SCIENCES HOLDINGS, INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Comera Life Sciences Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter, the “Corpo
May 25, 2022	EX-10.13	Registration Rights Agreement made and entered into as of May 19, 2022, between the Registrant and Maxim Group LLC (incorporated by reference to Exhibit 10.13 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 25, 2022). Exhibit 10.13 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of May 19, 2022, between Comera Life Sciences Holdings, Inc., a Delaware corporation (the ?Company?), and each of the purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to t
May 25, 2022	EX-10.5	Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by the Registrant on May 25, 2022). Exhibit 10.5 Name: Position: Effective Date: INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (?Agreement?), effective as of the effective date set forth above, is by and between Comera Life Sciences Holdings, Inc., a Delaware corporation (?Company?), and the director and/or officer of the Company identified above (?Executive?). Certain defined terms used in this Agreement are set forth in
May 25, 2022	EX-10.1	Comera Life Sciences, Inc. 2022 Incentive Award Plan. EX-10.1 4 d360099dex101.htm EX-10.1 Exhibit 10.1 Annex E COMERA LIFE SCIENCES, INC. 2022 EQUITY AND INCENTIVE PLAN Section 1. Purposes of the Plan The purposes of the Comera Life Sciences, Inc. 2022 Equity and Incentive Plan (the “Plan”) are: (i) to provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Comera Life Sciences
May 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 1-41403 87-4706968 (State or other jurisdiction of incorporation) (Com
May 25, 2022	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.2 11 d360099dex992.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2022 and the year ended December 31, 2021 give pro forma effect to the Business Combination as if it had occurred on January 1, 2022 and January 1, 2021, respectively. The unaudited pro
May 25, 2022	EX-99.1	INDEX TO FINANCIAL STATEMENTS Unaudited Condensed Financial Statements as of March 31, 2022 and December 31, 2021 and for the Three Months Ended March 31, 2022 and 2021 Page Balance Sheets F-2 Statements of Operations and Comprehensive Loss F-3 State EX-99.1 10 d360099dex991.htm EX-99.1 Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Unaudited Condensed Financial Statements as of March 31, 2022 and December 31, 2021 and for the Three Months Ended March 31, 2022 and 2021 Page Balance Sheets F-2 Statements of Operations and Comprehensive Loss F-3 Statements of Convertible Preferred Stock, Stockholders’ Deficit and Members’ Deficit F-4 Statements of C
May 25, 2022	EX-10.3	Registration Rights and Lock-up Agreement dated May 19, 2022, by and among the Registrant, OTR Acquisition Sponsor LLC and certain existing stockholders of Comera Life Sciences, Inc. and OTR Acquisition Corp. party thereto (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 25, 2022). Exhibit 10.3 REGISTRATION RIGHTS AND LOCK-UP AGREEMENT THIS REGISTRATION RIGHTS AND LOCK-UP AGREEMENT (this ?Agreement?), dated as of May 19, 2022, is made and entered into by and among, (i) Comera Life Sciences Holdings, Inc., a Delaware corporation (the ?Company?), (ii) OTR Acquisition Sponsor LLC, a Delaware limited liability company (the ?Sponsor?); (iii) certain holders of securities of OTR A
May 25, 2022	EX-2.2	First Amendment to Business Combination Agreement, dated as of May 19, 2022 among the Registrant, OTR Acquisition Corp., CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp. and Comera Life Sciences, Inc. (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 25, 2022). Exhibit 2.2 EXECUTION VERSION FIRST AMENDMENT TO BUSINESS COMBINATION AGREEMENT THIS FIRST AMENDMENT TO BUSINESS COMBINATION AGREEMENT (this ?Amendment?) is made as of May 19, 2022 (the ?Amendment Date?) by and among OTR Acquisition Corp., a Delaware corporation (?SPAC?), Comera Life Sciences Holdings, Inc., a Delaware corporation (?Holdco?), CLS Sub Merger 1 Corp., a Delaware corporation (?Compan
May 25, 2022	EX-10.12	Settlement and Release Agreement made and entered into as of May 19, 2022, between the Registrant and Maxim Group LLC (incorporated by reference to Exhibit 10.12 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 25, 2022). Exhibit 10.12 SETTLEMENT AND RELEASE AGREEMENT This SETTLEMENT AND RELEASE AGREEMENT (this ?Agreement?) is dated as of May 19, 2022, by and between OTR Acquisition Corp. (together with its parents, subsidiaries and affiliates, ?OTR?), Comera Life Sciences, Inc. (together with its parents, subsidiaries and affiliates, ?Comera Life Sciences?), Comera Life Sciences Holdings, Inc. (together with its p
May 19, 2022	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Comera Life Sciences Holdings, Inc. (Exact Name UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Comera Life Sciences Holdings, Inc.
May 10, 2022	425	Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation Filed by Comera Life Sciences Holdings, Inc./ OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Comera Life Sciences Holdings, Inc. (Commission File No. 333-263377) OTR Acquisition Corp. (Commission File No. 001-39708) Comera Life Sciences Announces Research Collaboration
May 5, 2022	S-1	Form S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on May 4, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 87-4706968 (State or Other Jurisdiction of In
May 5, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-4 (Form Type) Comera Life Sciences Holdings, Inc.
April 27, 2022	425	Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Comera Life Sciences Holdings, Inc. (Commission File No. 333-263377) OTR Acquisition Corp. (Commission File No. 001-39708) Comera Life Sciences to Present at 18th Annual PEGS Bo
April 19, 2022	425	Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Comera Life Sciences Holdings, Inc. (Commission File No. 333-263377) OTR Acquisition Corp. (Commission File No. 001-39708) Comera Life Sciences and Intas Pharmaceuticals Announc
April 18, 2022	425	Comera Life Sciences and OTR Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Comera Life Sciences Holdings, Inc. (Commission File No. 333-263377) OTR Acquisition Corp. (Commission File No. 333-263377) Comera Life Sciences and OTR Acquisition Corp. Announ
April 18, 2022	425	Corporate Presentation APRIL 2022 Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Comp Corporate Presentation APRIL 2022 Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Comera Life Sciences Holdings, Inc. (Commission File No. 333-263377) OTR Acquisition Corp. (Commission File No. 333-263377) Disclaimer These sl
April 15, 2022	424B3	Comera Life Sciences Holdings, Inc. 41,330,050 Shares of Common Stock 11,041,432 Warrants Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-263377 PROXY STATEMENT/PROSPECTUS Comera Life Sciences Holdings, Inc. 41,330,050 Shares of Common Stock 11,041,432 Warrants On January 31, 2022, Comera Life Sciences Holdings, Inc., a Delaware corporation (?Holdco?), CLS Sub Merger 1 Corp., a Delaware corporation and newly formed, wholly-owned subsidiary of Holdco (?Comera Mer
April 13, 2022	CORRESP	Comera Life Sciences Holdings, Inc. 12 Gill Street Suite 4650 Woburn, Massachusetts 01801 Tel: (617) 871-2101 Comera Life Sciences Holdings, Inc. 12 Gill Street Suite 4650 Woburn, Massachusetts 01801 Tel: (617) 871-2101 April 13, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell and Celeste Murphy Re: Comera Life Sciences Holdings, Inc. Registration Statement on Form S-4 File No. 333-263377 Dear Mr. Cam
April 11, 2022	EX-99.1	Form of Preliminary Proxy Card to be used by OTR Acquisition Corp. EX-99.1 5 d299220dex991.htm EX-99.1 Exhibit 99.1 FOR THE SPECIAL MEETING OF OTR ACQUISITION CORP. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS P R O X Y The undersigned hereby appoints Nicholas J. Singer and Douglas B. Anderson (together, the “Proxies”), and each of them independently, with full power of substitution, as proxies to vote the shares that the undersigned is entitled to
April 11, 2022	EX-21.1	List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Comera Life Sciences, Inc. Subsidiary Name State or other jurisdiction of incorporation or organization Names under which such subsidiaries do business CLS Sub Merger 1 Corp. Delaware subsidiary name CLS Sub Merger 2 Corp. Delaware subsidiary name List of Subsidiaries of OTR Acquisition Corp. None
April 11, 2022	EX-4.2	Specimen Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to Amendment No. 3 to the registration statement on Form 2-4, filed by the Registrant with the SEC on April 11, 2022). Exhibit 4.2 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP COMERA LIFE SCIENCES HOLDINGS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE COMMON STOCK OF COMERA LIFE SCIENCES HOLDINGS, INC. (THE ?COMPANY?) transferable on the books of the Company in pe
April 11, 2022	S-4/A	Stockholder Support Agreement, dated as of January 31, 2022, by and among the Registrant, OTR Acquisition Corp., Comera Life Sciences, Inc. and certain stockholders of Comera Life Sciences, Inc. party thereto (incorporated by reference to Annex F to Amendment No. 3 to the registration statement on Form S-4, filed by the Registrant with the SEC on April 11, 2022). Table of Contents As filed with the U.S. Securities and Exchange Commission on April 11, 2022 Registration No. 333-263377 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 87-4706968 (State
April 6, 2022	S-4/A	As filed with the U.S. Securities and Exchange Commission on April 6, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 6, 2022 Registration No. 333-263377 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Comera Life Sciences Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 87-4706968 (State

CMRA / Comera Life Sciences Holdings, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)